Wachovia Ups Biogen Idec to 'Outperform'
Wachovia upgraded Biogen Idec (BIIB ) to outperform from market perform. Yesterday the company and Elan (ELN ) said they expect to submit an application to FDA for approval of Antegren by mid-2004.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Bitcoin Futures Deliver Wild Ride as Debut Brings Rally, Halts
- Investors Told to Brace for Steepest Rate Hikes Since 2006
- A Manager of $42 Billion Fears Bubble in World's Biggest Stocks
- Longtime NPR Host Tom Ashbrook Is Facing Misconduct Allegations
- Buffett's About to Get $3 Billion Back From Burger King Owner